Market Access of Biosimilars in Europe - Biosimilar uptake in Europe, Aut idem and rebate contracts in Germany

- Biosimilars markets in Europe: Navigating market access barriers - Demand-side measures to ensure biosimilar uptake in Europe - Aut idem in Germany - the current rules - Rebate contracts for biosimilars - Regulatory update Biosimilars - current status of authority guidancesBiosimilar uptake in Europe, Aut idem in Germany - these are the challenges for regulatory affairs and market accessLernzieleThis training course provides comprehensive insights into the European biosimilars landscape. Participants will gain a deep understanding of current market dynamics, regulatory frameworks, and access strategies across Europe, with a special focus on recent developments in Germany.- By the end of this course, you will be equipped with practical knowledge of regulatory and market access pathways for biosimilars in Europe and know how the new rules in Germany affect your market access and healthcare management.ZielgruppenThis training course is aimed at regulatory affairs and market access specialists in the pharmaceutical industry who bring biosimilar products to the market. It is also of value to all those working in health insurance companies dealing with pharmaceuticals in their work.